CAS: 25486-55-9; 1A-Methyl-7A-(3,7,11,15-Tetramethylhexadec-2-En-1-yl)-1A,7A-Dihydronaphtho[2,3-B]Oxirene-2,7-Dione

该化合物是维生素K的衍生物,在合成血液凝固和骨代谢所需的某些蛋白质方面起着关键作用,该化合物的特点是其四氧化物功能组,有助于其再活性和生物活动.维生素K 氧化物通常是在维生素K代谢期间形成的,可通过酶分解而恢复其活性形式.这是一种脂肪溶质化合物,意谓它溶于脂肪和有机溶剂,但不在水中.这种特性影响其吸收和在生物系统中的迁移.维生素K循环是维他命K,它对于保持体内活性维生素K的适当水平至关重要.其存在和水平可以表明维生素K的状况,并可能对各种健康状况产生影响,尤其是与凝固性失调有关的情况.

结构式图片

物理性质

MSDS等安全信息

上下游产品

CAS号81818-54-4 维生素K-1 | CAS号16869-68-4 2-methyl-3-(3,7...

合成工艺路线路线简述

  • 合成目标产物 (2,3-Epoxyphytyl)Menaquinone 主要起始原料 2-Methyl-3-(3,7,11,15-Tetramethylhexadec-2-Enyl)-1,4-Naphthoquinone
  • (文献来源)合成步骤主要原料 2-Methyl-3-(3,7,11,15-Tetramethylhexadec-2-Enyl)-1,4-Naphthoquinone
📜维生素k 在 Sodium Hydroxide,(-)-N-Benzylquininium Chloride,双氧水体系中,用 甲苯作为反应溶剂,以68%的收率获得vitamin K1 Epoxide
参考文献:Absolute Configuration Of Vitamin K Epoxide
标题:Absolute Configuration Of Vitamin K Epoxide
摘要:
Doi:10.1021/Jo00161A034

海关参考信息

专利信息


专利号:US-6864279-B2
优先权日:2001-04-24
标 题 :Materials and methods for treating coagulation disorders
发明人：DRUZGALA PASCAL; ZHANG XIAOMING; PFISTER JUERG
权利人:ARYX THERAPEUTICS
摘要:This invention is drawn to compounds which are more easily metabolized by the metabolic drug detoxification systems. Particularly, warfarin analogs which have been designed to include esters within the structure of the compounds are taught. The invention teaches methods of reducing the toxicity of drugs comprising the introduction of ester groups into drugs during the synthesis of the drug. This invention is also drawn to methods of treating coagulation disorders comprising the administration of compounds which have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester containing warfarin, analogs are also taught.

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

⚠️全国化工行业净网倡议书
📋制造商识别码
📖 海关编码查询
📝MSDS生成器

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献


摘要:Dembitsky, V. M.; Vil’, V. A., Science of Synthesis Knowledge Updates, (2019) 3, 344.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知